Many more abuse-deterrent formulations are entering the market. In November 2014 the FDA approved Hysingla ER (hydrocodone bitartrate), an acetaminophen-free, extended-release (ER) opioid for severe pain requiring daily, long-term treatment and for which no alternatives exist. As with other abuse-deterrent forms, Hysingla ER abuse-deterrent properties may reduce, but not totally prevent, abuse of the drug. The tablet forms a thick gel and cannot be easily prepared for injection, and is difficult to crush, break or dissolve. The most common side effects of Hysingla ER are constipation, nausea, fatigue, and dizziness. Targiniq ER (oxycodone/naloxone), Oxycontin (oxycodone [reformulated]), Embeda (morphine/naltrexone), Zohydro ER (hydrocodone), Troxyca ER (naltrexone/oxycodone), Arymo ER (morphine sulfate extended-release tablet), and Vantrela ER (hydrocodone bitartrate) are other long-acting but abuse-deterrent pain medications.